Sio Gene Therapies Inc. (SIOX) Financial Statements (2024 and earlier)

Company Profile

Business Address 1501 BROADWAY
NEW YORK, NY 10036
State of Incorp.
Fiscal Year End March 31
Industry (SIC) 2834 - Pharmaceutical Preparations (benchmarking)
More info Complete Financial Analysis Financial Benchmarking

Balance Sheet (Statement of Financial Position) (USD)

12/31/2022
Q3
9/30/2022
Q2
6/30/2022
Q1
3/31/2022
Q4
12/31/2021
Q3
9/30/2021
Q2
6/30/2021
Q1
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments49,865,00054,771,00063,729,00081,910,000101,695,000110,976,000
Cash and cash equivalents49,865,00054,771,00063,729,00081,910,000101,695,000110,976,000
Restricted cash and investments 1,184,0001,184,0001,184,0001,184,0001,184,000 
Receivables355,000355,0001,609,0001,732,0001,733,0001,681,000
Other undisclosed current assets2,335,0002,821,0005,214,0005,244,0004,321,0006,276,000
Total current assets:53,739,00059,131,00071,736,00090,070,000108,933,000118,933,000
Noncurrent Assets
Operating lease, right-of-use asset 7,0002,267,0002,444,0002,613,0001,052,0001,103,000
Property, plant and equipment  1,084,000900,000623,000548,000595,000
Restricted cash and investments      1,184,000
Total noncurrent assets: 7,0003,351,0003,344,0003,236,0001,600,0002,882,000
TOTAL ASSETS:53,746,00062,482,00075,080,00093,306,000110,533,000121,815,000
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities5,804,0008,996,00012,216,00014,373,00010,039,0007,326,000
Taxes payable499,000   
Employee-related liabilities475,000655,000   
Accounts payable1,963,0002,240,0003,984,0006,611,0002,673,000937,000
Accrued liabilities2,867,0006,101,0008,232,0007,762,0007,366,0006,389,000
Other undisclosed current liabilities (970,000)153,000786,000765,000269,000269,000
Total current liabilities:4,834,0009,149,00013,002,00015,138,00010,308,0007,595,000
Noncurrent Liabilities
Long-term debt and lease obligation:  1,554,0001,730,0001,903,000865,000921,000
Operating lease, liability  1,554,0001,730,0001,903,000865,000921,000
Other undisclosed noncurrent liabilities  (1,554,000)(1,730,000)(1,903,000)(865,000)(921,000)
Total noncurrent liabilities:  1,554,000 1,903,000865,000921,000
Total liabilities:4,834,00010,703,00014,732,00017,041,00011,173,0008,516,000
Equity
Equity, attributable to parent48,912,00051,779,00060,348,00076,265,00099,360,000113,299,000
Common stock1,0001,0001,0001,0001,0001,000
Additional paid in capital923,022,000922,807,000922,966,000925,558,000923,198,000915,900,000
Accumulated other comprehensive income331,000333,000337,000338,000337,000337,000
Accumulated deficit(874,442,000)(871,362,000)(862,956,000)(849,632,000)(824,176,000)(802,939,000)
Total equity:48,912,00051,779,00060,348,00076,265,00099,360,000113,299,000
TOTAL LIABILITIES AND EQUITY:53,746,00062,482,00075,080,00093,306,000110,533,000121,815,000

Income Statement (P&L) (USD)

12/31/2022
Q3
9/30/2022
Q2
6/30/2022
Q1
3/31/2022
Q4
12/31/2021
Q3
9/30/2021
Q2
6/30/2021
Q1
Operating expenses(3,277,000)(8,534,000)(41,574,000)(25,373,000)(21,196,000)(11,917,000)
Other undisclosed operating income (loss)197,000124,000(656,000)(83,000)(41,000)19,000
Operating loss:(3,080,000)(8,410,000)(42,230,000)(25,456,000)(21,237,000)(11,898,000)
Interest and debt expense   771,000(7,000)(11,000)(1,000)
Loss from continuing operations before equity method investments, income taxes:(3,080,000)(8,410,000)(41,459,000)(25,463,000)(21,248,000)(11,899,000)
Other undisclosed income from continuing operations before income taxes   27,000   
Loss from continuing operations before income taxes:(3,080,000)(8,410,000)(41,432,000)(25,463,000)(21,248,000)(11,899,000)
Income tax expense (benefit)  4,000(563,000)  28,000
Loss from continuing operations:(3,080,000)(8,406,000)(41,995,000)(25,463,000)(21,248,000)(11,871,000)
Loss before gain (loss) on sale of properties:(3,080,000)(8,406,000)(41,995,000)(25,463,000)(21,248,000)(11,871,000)
Net loss:(3,080,000)(8,406,000)(41,995,000)(25,463,000)(21,248,000)(11,871,000)
Other undisclosed net income (loss) attributable to parent   (798,000)7,00011,0001,000
Net loss available to common stockholders, diluted:(3,080,000)(8,406,000)(42,793,000)(25,456,000)(21,237,000)(11,870,000)

Comprehensive Income (USD)

12/31/2022
Q3
9/30/2022
Q2
6/30/2022
Q1
3/31/2022
Q4
12/31/2021
Q3
9/30/2021
Q2
6/30/2021
Q1
Net loss:(3,080,000)(8,406,000)(41,995,000)(25,463,000)(21,248,000)(11,871,000)
Comprehensive loss:(3,080,000)(8,406,000)(41,995,000)(25,463,000)(21,248,000)(11,871,000)
Other undisclosed comprehensive income (loss), net of tax, attributable to parent (2,000)(4,000)(1,194,000)8,00011,0003,000
Comprehensive loss, net of tax, attributable to parent:(3,082,000)(8,410,000)(43,189,000)(25,455,000)(21,237,000)(11,868,000)

Statements Sources

The financial statements are based on the Company's filings with the U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: